Noninvasive Assessment of Cerebral Oxygenation and Cardiac Function in Patients With Neurovascular Diseases
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Bengaluru, India
- NIMHANS
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- aneurysmal subarachnoid hemorrhage
- potential or actual cerebral vasospasm
Exclusion Criteria:
- non-aneurysmal subarachnoid hemorrhage
- outside the 4-21 day window after ictus
- peripheral deoxygenation
- contraindication for nimodipine administration
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in the cerebral oxygen saturation percentage measured using near infrared spectroscopy technology after administration of nimodipine
Time Frame: Change from baseline cerebral oxygen saturation at 30 minutes after administration of nimodipine
|
Change from baseline cerebral oxygen saturation at 30 minutes after administration of nimodipine
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the cardiac output measured using near NICOM technology after administration of nimodipine
Time Frame: Change from baseline cardiac output at 30 and 240 minutes after administration of nimodipine
|
unit of measurement will be L/min
|
Change from baseline cardiac output at 30 and 240 minutes after administration of nimodipine
|
|
Change in the cerebral oxygen saturation percentage measured using near infrared spectroscopy technology after administration of nimodipine
Time Frame: Change from baseline cerebral oxygen saturation at 240 minutes after administration of nimodipine
|
Change from baseline cerebral oxygen saturation at 240 minutes after administration of nimodipine
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Intracranial Hemorrhages
- Hemorrhage
- Subarachnoid Hemorrhage
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Nimodipine
Other Study ID Numbers
Other Study ID Numbers
- 12.02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.